Navigation Links
Zeus to Present at Digestive Disease Week in Chicago
Date:5/29/2009

Zeus Research & Development will be one of the presenters at Digestive Disease Week, addressing the topic of invention of new devices in interventional gastroenterology

ORANGEBURG, S.C., May 29 /PRNewswire/ -- Zeus, Inc., a leader in polymer extrusions and material science, announces it has been invited to present at Digestive Disease Week in Chicago on June 1, 2009. Zeus presenters Dr. Bruce Anneaux, Ph.D. and GI Endoscopy Specialist Aubrey Sanders will address possible polymer selection for building new and innovative medical devices for interventional procedures in gastrointestinal endoscopy and Natural Orifice Translumenal Endoscopic Surgery (NOTES).

Digestive Disease Week is the world's largest meeting of researchers, physicians, and other professionals in the fields of gastroenterology, endoscopy, gastrointestinal surgery, and hepatology.

When Dr. Naomi Nakao, a prolific inventor of 20 years extended her invitation to Zeus to speak at the conference, she prefaced her invitation as follows: "Being an inventor can be a lonely journey, but Zeus has faithfully stood by me for these many years. Zeus engineers have generously helped me during my research and development of the many prototypes of my inventions. I was gently brought down to earth by Zeus engineers, learning what is, and is not, possible in building my devices. Sharing their company's varied capabilities, I learned from Zeus' engineers that things I did not think possible could be built because of the enormous imagination that Zeus puts into its colossal ensemble of shapes, forms, colors, and sizes of the catheters and other sub-components that it has to offer."

The Zeus presentation will focus primarily on developing industry advancements in polymer science with an emphasis on gastroenterology and endoscopy of the present and future. At the conclusion of the presentation, Dr. Anneaux and Ms. Sanders will participate in an open panel discussion.

Commenting on his presentation Dr. Bruce Anneaux, Corporate Manager, Research & Development for Zeus, said, "We are excited about the opportunity to present at a gathering of this scope and significance. Both the Zeus presentation and open panel discussion seek to enhance attendees' understanding of polymer selection and create an open dialogue among the innovators in gastroenterology/endoscopy medical device industry."

Bob Jennings, Vice President for Medical Sales and Marketing, said, "Zeus has an evolving history of exploring and advancing innovative concepts and processes in the medical device industry. It is this commitment that allows us to serve as a resource for inventors, physicians, and other professionals who strive to enhance medical applications and ultimately, improve patient care."

About Zeus, Inc.:

Zeus, Inc. is headquartered in Orangeburg, SC, USA. Zeus is a world leader in material science and the development of high-performance polymer tubing used in demanding applications, operating multiple facilities in North America and internationally. Zeus products and services are preferred by companies in medical, automotive, electrical, fluid handling, and mechanical markets. For more information, visit http://www.zeusinc.com.

    Press Contact:

    Samantha D. Farlow
    Zeus, Inc.
    Communications Coordinator
    publicrelations@zeusinc.com
    (803) 268-9505

This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.


'/>"/>
SOURCE Zeus, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Oral VDA CYT997 - Phase I Clinical Trial Presentation at ASCO
2. YM BIOSCIENCES ANNOUNCES RESULTS OF RANDOMIZED NIMOTUZUMAB STUDY TO BE PRESENTED IN A POSTER AT ASCO ANNUAL MEETING
3. Centocor Ortho Biotech Data to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting
4. Quest Diagnostics to Present Genomic Studies Related to New Testing Techniques for Leukemia and Prostate Cancer at 2009 ASCO Meeting
5. BioMS Medical to present at the 2009 Symposium for the Canadian Society for Pharmaceutical Sciences
6. Intarcia Therapeutics, Inc. Announces Acceptance of ITCA 650 Phase 1b Study for Late-Breaker Presentation at the American Diabetes Association 69th Scientific Sessions
7. Clinical Data on Peregrines Bavituximab Cancer Program to Be Discussed in Two Presentations at 2009 ASCO Annual Meeting
8. Senesco Presents Pre-Clinical Multiple Myeloma Data at the 12th Annual Meeting of the American Society of Gene Therapy
9. Lexicon to Present Clinical Data for LX1031 and LX1032 at Digestive Disease Week
10. POET to Outline Cellulosic Ethanol's Present, Future at Brazil's Ethanol Summit 2009
11. InspireMD Announce the Completion of Enrollment for the MAGICAL Trial (MGuard(TM) in Acute Myocardial Infarction) at EuroPCR 09. Results Will be Presented May 21st by Dr. Dariusz Dudek at the InspireMD Cocktail Reception Debate Chaired by Prof. Martin Le
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... 2017 Interpace Diagnostics Group, Inc. (NASDAQ: ... clinically useful molecular diagnostic tests and pathology services, ... securities purchase agreement with three  institutional investors to ... stock in a registered direct offering.  In a ... sell to the same investors warrants to purchase ...
(Date:1/21/2017)... CAMBRIDGE, Mass. , Jan. 21, 2017   ... of novel compounds designed to target cancer stemness pathways, ... lead investigational compound, napabucasin, at the 2017 American Society ... San Francisco . In ... administered investigational agent designed to inhibit cancer stemness pathways ...
(Date:1/20/2017)... , Jan. 20, 2017 Ginkgo ... of Gen9, a pioneer in the synthesis and ... unique expertise in assembling pathway-length synthetic DNA into ... and capacity in the construction of new organism ... industries. "Gen9 was founded to significantly ...
(Date:1/19/2017)... 2017 Research and Markets has announced the ... Cancer Type, Application - Global Opportunity Analysis and Industry Forecast, 2014-2022" ... ... market is projected to reach $15,737 million by 2022 from $6,521 ... 2022. Omic technologies segment accounted for more than ...
Breaking Biology Technology:
(Date:12/12/2016)... , Dec. 12, 2016  Researchers at ... possibilities for graphene by combining the material with ... highly sensitive pressure detector able to sense pulse, ... a small spider.  The research ... can be read here:  http://science.sciencemag.org/content/354/6317/1257 ...
(Date:12/8/2016)... 8, 2016  Singulex, Inc., the leader in Next ... into a license and supply agreement with Thermo Fisher ... provides Singulex access to Thermo Scientific BRAHMS PCT (Procalcitonin), ... is used to diagnose systemic bacterial infection and sepsis ... to aid in assessing the risk of critically ill ...
(Date:12/7/2016)... , December 7, 2016 BioCatch , ... expansion of its patent portfolio, which grew to over 40 granted and ... , , ... recently filed patent entitled " System, Device, and Method Estimating ... that enables device makers to forego costly hardware components needed to estimate ...
Breaking Biology News(10 mins):